Precigen rises after US FDA approves drug for rare respiratory disease

Shares of drugmaker Precigen PGEN.O surge 62.2% to a near four-year high of $3 in morning trade

Stock set for its best day in over five years, if gains hold

U.S. FDA approves PGEN's drug to treat adults with a rare respiratory disease, making it the first treatment for the condition to receive the health regulator's nod

Papzimeos is approved to treat recurrent respiratory papillomatosis (RRP), a condition that causes growth of wart-like tumors in the respiratory tract due to human papillomavirus (HPV) infection

Including session's move, stock up 155.4% YTD